Shares of 23andMe Holding Co. (ME) are up over 20% at $1.33 in premarket trading Friday, following FDA clearance to expand its existing BRCA1/BRCA2 Genetic Health Risk Report.
A Genetic Health Risk report indicates the presence of specific genetic variants linked to an increased likelihood of developing a disease although it does not describe a person's overall risk of developing the disease.
The new FDA clearance allows 23andMe to report an additional 41 variants in the BRCA1 and BRCA2 genes known to be associated with higher risk for breast, ovarian, prostate and pancreatic cancer.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.